Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Contineum Therapeutics (CTNM) Income from Continuing Operations (2023 - 2025)

Contineum Therapeutics (CTNM) has 3 years of Income from Continuing Operations data on record, last reported at 15105000.0 in Q4 2025.

  • For Q4 2025, Income from Continuing Operations fell 3.71% year-over-year to 15105000.0; the TTM value through Dec 2025 reached 59813000.0, down 41.54%, while the annual FY2025 figure was 59813000.0, 41.54% down from the prior year.
  • Income from Continuing Operations reached 15105000.0 in Q4 2025 per CTNM's latest filing, down from 12975000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 41600000.0 in Q2 2023 and bottomed at 15873000.0 in Q2 2025.
  • Average Income from Continuing Operations over 3 years is 6612583.33, with a median of 9638000.0 recorded in 2024.
  • Peak YoY movement for Income from Continuing Operations: tumbled 121.66% in 2024, then fell 3.71% in 2025.
  • A 3-year view of Income from Continuing Operations shows it stood at 7787000.0 in 2023, then plummeted by 87.04% to 14565000.0 in 2024, then fell by 3.71% to 15105000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Income from Continuing Operations were 15105000.0 in Q4 2025, 12975000.0 in Q3 2025, and 15873000.0 in Q2 2025.